A failed drug trial in non-small lung Ca & another one with pre-treatment & combo therapy trial. The comment of Novel treatment beyond targeting T-cells was interesting:
“The study, called EMERGE, was testing three dose levels of Jounce’s drug, vopratelimab, with Opdivo in 59 patients who had already tried PD-1 or PD-L1 inhibitors like Bristol Myers Squibb’s Opdivo or Merck’s Keytruda. Yervoy works by targeting CTLA-4, a receptor found on T cells that acts as a “brake” on the immune system. Adding vopratelimab to the mix, Jounce thought, would activate ICOS, a different protein on the T cells, to boost their proliferation and expansion after Yervoy released the immune brake. But data from 50 evaluable patients said otherwise.”
https://www.fiercebiotech.com/biotech/jounce-sinks-as-it-ditches-phase-2-yervoy-combo-trial“The PD-(L)1 experienced or resistant population continues to prove difficult to treat. To bring necessary benefit to these patients it is becoming clearer that novel approaches beyond T cells may be needed as part of the solution,” Jounce CEO Richard Murray, Ph.D., said in the statement.
- Forums
- ASX - By Stock
- IMU
- Media Thread
Media Thread, page-60
-
-
- There are more pages in this discussion • 14,863 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
|
|||||
Last
5.4¢ |
Change
-0.001(1.82%) |
Mkt cap ! $396.8M |
Open | High | Low | Value | Volume |
5.5¢ | 5.6¢ | 5.4¢ | $443.4K | 8.072M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
27 | 3056419 | 5.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.5¢ | 120000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
27 | 3056419 | 0.054 |
23 | 3628513 | 0.053 |
21 | 2089051 | 0.052 |
21 | 1993914 | 0.051 |
67 | 4445029 | 0.050 |
Price($) | Vol. | No. |
---|---|---|
0.055 | 120000 | 1 |
0.056 | 798869 | 9 |
0.057 | 1637593 | 13 |
0.058 | 320000 | 3 |
0.059 | 467000 | 5 |
Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |